Mumbai, Oct. 14 -- In the Pathology business, franchise revenue grew by 20% year-on-year, while partnership revenue recorded a robust 35% year-on-year growth.

Thyrocare processed 53.3 million tests in Q2FY26, marking a strong 21% year-on-year growth.

Reported EBITDA improved by 48% to Rs 71.45 crore in Q2 FY26 from Rs 48.22 crore in Q2 FY25. Reported EBITDA for Q2 FY26 was 33% as against 27% in Q2 FY25.

Profit before tax in Q2 FY26 stood at Rs 62.58 crore, up by 70% from Rs 36.78 crore in Q2 FY25.

The company is debt-free on a consolidated basis and holds a net cash and cash equivalents including short-term investments of over Rs 190 crore.

The company's board of directors has approved issuance of bonus shares in the proportion of 2:...